Enzymatic Synthesis of D-pipecolic Acid by Engineering the Substrate Specificity of Trypanosoma cruzi Proline Racemase and Its Molecular Docking Study
- 11 Downloads
Pipecolic acid is an unnatural amino acid mostly used for pharmaceutical purposes. Pipecolic acid has two types of enantiomers with different roles in the synthesis of drugs. The development of efficient catalytic methods for the production of enantiopure pipecolic acid is currently a crucial topic of research. Few chemo- or biosynthetic methods have been proposed for the synthesis of pure enantiomers; however, enzymatic conversion of the chirality of pipecolic acid has not been demonstrated because no pipecolic acid racemase has been reported yet. In this work, we attempted to engineer pipecolic acid racemase activity into Trypanosoma cruzi proline racemase (TcPRAC) for the enzymatic synthesis of D-pipecolic acid from L-pipecolic acid. For the binding of pipecolic acid (C6 ring) into the active site of TcPRAC, which was optimized for the original substrate proline (C5 ring), four bulky aromatic residues (Phe102, Phe120, Phe220, and Phe 290) of TcPRAC were mutated to smaller hydrophobic residues. Among the mutants, six single-point mutants (F102A, F102I, F102L, F102V, F290L, and F290V) exhibited significant racemase activity against L-pipecolic acid. The most efficient variant, F102V, showed 74% racemization. Molecular docking simulations revealed that lowering the binding energy of L-pipecolic acid to the active site was important for achieving high racemization activity of TcPRAC mutant proteins.
KeywordsD-pipecolic acid enzymatic synthesis substrate specificity engineering Trypanosoma cruzi proline racemase racemization
Unable to display preview. Download preview PDF.
- 10.Germann, U. A., D. Shlyakhter, V. S. Mason, R. E. Zelle, J. P. Duffy, V. Galullo, D. M. and J. O. Saunders, J. Boger, and M. W. Harding (1997) Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of Pglycoprotein-mediated multidrug resistance in vitro. ANTICANCER DRUGS 8: 125–140.CrossRefGoogle Scholar
- 11.Pettibone, D. J., B. V. Clineschmidt, P. S. Anderson, R. M. Freidinger, G. F. Lundell, L. R. Koupal, C. D. Schwartz, J. M. Williamson, M. A. Goetz, O. D. Hensens, J. M. Liesch, and J. P. Springer (1989) A structurally unique, potent, and selective oxytocin antagonist derived from Streptomyces silvensis. ENDOCRINOLOGY 125: 217–222.CrossRefGoogle Scholar
- 15.Darkin-Rattray, S. J., A. M. Gurnett, R. W. Myers, P. M. Dulski, T. M. Crumley, J. J. Allocco, C. Cannova, P. T. Meinke, S. L. Colletti, M. A. Bednarek, S. B. Singh, M. A. Goetz, A. W. Dombrowski, J. D. Polishook, and D. M. Schmatz (1996) Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase. Proceedings of the National Academy of Sciences of the United States of America 93: 13143–13147.CrossRefGoogle Scholar
- 27.Buschiazzo, A., M. Goytia, F. Schaeffer, W. Degrave, W. Shepard, C. Grégoire, N. Chamond, A. Cosson, A. Berneman, N. Coatnoan, P. M. Alzari, and P. Minoprio (2006) Crystal structure, catalytic mechanism, and mitogenic properties of Trypanosoma cruzi proline racemase. Proceedings of the National Academy of Sciences of the United States of America 103: 1705–1710.CrossRefGoogle Scholar